Trigeminal Neuralgia: Diagnosis, Differential Diagnosis and Contemporary Management

Trigeminal neuralgia (TN), also known as tic douloureux, is a chronic orofacial pain disorder characterized by recurrent, unilateral, brief, electric shock-like pain in the distribution of one or more divisions of the trigeminal nerve. It is widely regarded as one of the most severe pain conditions known to medical science, with profound impacts on quality of life, nutrition, and psychological well-being. Dental professionals are often the first clinicians consulted by patients with TN, as the pain is frequently perceived as arising from the teeth or jaws, leading to unnecessary dental procedures before the correct diagnosis is established.

Classification and Epidemiology

The International Classification of Headache Disorders (ICHD-3) and the International Association for the Study of Pain classify TN into three subtypes. Classical TN is caused by neurovascular compression of the trigeminal nerve root by a blood vessel, typically the superior cerebellar artery, resulting in focal demyelination and ephaptic transmission. Secondary TN is attributable to an identifiable underlying neurological disease other than neurovascular compression, such as multiple sclerosis (MS), cerebellopontine angle tumors, or arteriovenous malformations. Idiopathic TN is diagnosed when no causative lesion is identified on imaging or during posterior fossa exploration.

TN has an annual incidence of approximately 4 to 13 per 100,000 individuals, with a slight female predominance (female-to-male ratio of 1.5:1). The mean age of onset is in the sixth decade of life, though TN associated with MS presents at a younger age. The maxillary (V2) and mandibular (V3) divisions are most commonly affected, either in isolation or combination. Bilateral involvement is rare (3% to 5%) and should raise suspicion for MS.

Clinical Presentation

The hallmark of TN is paroxysmal, lancinating pain lasting from a fraction of a second to two minutes, with pain-free intervals between attacks. Patients describe the pain as sharp, shooting, stabbing, or "like an electric shock." Pain is strictly unilateral and confined to the trigeminal distribution. Trigger zones, or "trigger points," are small areas on the facial skin or oral mucosa where light mechanical stimulation — such as touching, washing, shaving, brushing teeth, talking, chewing, or even a breeze — can provoke an attack. These trigger zones are pathognomonic for TN and are a key diagnostic feature.

Classical TN often exhibits a relapsing-remitting course, with periods of remission lasting months to years, though the frequency and severity of attacks tend to increase over time. Some patients develop a concomitant continuous, burning, or aching background pain between paroxysms, known as TN with concomitant continuous pain, which represents a more severe and treatment-resistant phenotype.

Pathophysiology

The prevailing theory for classical TN is the neurovascular compression hypothesis. An aberrant arterial loop, most commonly the superior cerebellar artery, compresses the trigeminal nerve root at its entry zone into the pons, a transition zone between central and peripheral myelin. This chronic pulsatile compression causes focal demyelination and remyelination, leading to abnormal hyperexcitability, ectopic impulse generation, and ephaptic cross-talk between adjacent nerve fibers. Light tactile stimuli carried by large myelinated A-beta fibers can then trigger high-frequency discharges in nociceptive A-delta and C fibers, producing the characteristic paroxysmal pain.

In MS-related TN, demyelinating plaques within the trigeminal root entry zone or brainstem trigeminal nuclei produce similar electrophysiological derangements. Peripheral and central sensitization mechanisms are believed to underlie the transition from purely paroxysmal pain to TN with concomitant continuous pain.

Diagnosis and Differential Diagnosis

The diagnosis of TN is primarily clinical, based on the characteristic history and exclusion of other pathologies. A thorough history is paramount, with emphasis on pain quality, distribution, duration, triggers, and the presence of refractory periods. Neurological examination should be normal in classical TN; any sensory or motor deficit in the trigeminal distribution should prompt investigation for secondary causes.

High-resolution magnetic resonance imaging (MRI) with three-dimensional constructive interference in steady state or fast imaging employing steady-state acquisition sequences is the imaging modality of choice. It enables visualization of the trigeminal nerve, assessment of neurovascular contact, and exclusion of structural lesions such as tumors, MS plaques, and vascular malformations. Magnetic resonance angiography may be added to delineate the offending vessel.

The differential diagnosis of TN includes other trigeminal neuropathic pain conditions, temporomandibular disorders, dental pain (pulpitis, cracked tooth syndrome, atypical odontalgia), cluster headache and other trigeminal autonomic cephalalgias, postherpetic neuralgia, and glossopharyngeal neuralgia. Persistent idiopathic facial pain (atypical facial pain) presents as continuous, poorly localized pain without trigger zones or paroxysms, distinct from TN. Careful clinical differentiation prevents unnecessary and irreversible dental interventions, including extractions, root canal treatments, and exploratory surgeries.

Pharmacological Management

Carbamazepine is the first-line pharmacological treatment for TN, supported by the highest level of evidence. It provides initial complete or near-complete pain relief in 70% to 80% of patients. The starting dose is 100 to 200 mg twice daily, titrated slowly to effect, with a typical maintenance dose of 400 to 1200 mg daily. Oxcarbazepine, a keto-analogue of carbamazepine, offers comparable efficacy with fewer drug interactions and a more favorable side effect profile, and is increasingly preferred as initial therapy at doses of 600 to 1800 mg daily.

Adverse effects of carbamazepine include dizziness, drowsiness, ataxia, nausea, hyponatremia, and rarely, agranulocytosis, aplastic anemia, and Stevens-Johnson syndrome (particularly in HLA-B*1502-positive individuals of Asian ancestry). Routine hematological and hepatic monitoring is recommended. Second-line agents include lamotrigine, baclofen, gabapentin, and pregabalin, used either as monotherapy in patients intolerant of first-line agents or as adjunctive therapy for refractory cases. Emerging evidence supports the use of botulinum toxin type A injections into the trigger zones for medically refractory TN.

Surgical Management

Surgical intervention is indicated for patients with medically refractory TN, intolerable medication side effects, or secondary TN with an identifiable structural lesion. Microvascular decompression (MVD) is the most definitive surgical procedure, directly addressing the neurovascular compression etiology. A retrosigmoid craniotomy is performed to access the posterior fossa, and the offending vessel is separated from the trigeminal nerve root using a Teflon felt or Ivalon sponge. MVD provides the highest rate of long-term pain relief, with 70% to 80% of patients remaining pain-free at 10 years. Risks include cranial nerve deficits (hearing loss, facial palsy), cerebrospinal fluid leak, cerebellar injury, and a mortality rate of approximately 0.2% to 0.5%.

Ablative procedures target the trigeminal nerve or ganglion to interrupt pain transmission. Percutaneous radiofrequency thermocoagulation (RFT) produces selective destruction of nociceptive fibers through controlled thermal lesions of the Gasserian ganglion. It provides immediate pain relief in over 90% of patients, but sensory complications including facial numbness, dysesthesia, and anesthesia dolorosa are common. Glycerol rhizolysis and percutaneous balloon microcompression are alternative percutaneous techniques with similar efficacy and side effect profiles.

Stereotactic radiosurgery (Gamma Knife, CyberKnife) delivers focused radiation to the trigeminal root entry zone, producing gradual axonal degeneration and pain relief over weeks to months. It is minimally invasive and particularly suited for elderly patients or those with medical comorbidities precluding open surgery. Pain relief rates of 70% to 90% are reported, with facial sensory disturbance as the primary complication. Recurrence rates are higher than MVD, and the procedure can be repeated if necessary.

Conclusion

Trigeminal neuralgia is a debilitating neuropathic pain disorder that requires early and accurate diagnosis to prevent unnecessary dental interventions and to initiate appropriate, evidence-based management. Carbamazepine and oxcarbazepine remain the pharmacological mainstays. Microvascular decompression offers the best chance for long-term pain freedom in suitable surgical candidates, while percutaneous and radiosurgical procedures provide effective alternatives for patients who are not candidates for open surgery. A multidisciplinary approach involving neurology, neurosurgery, and pain management optimizes outcomes for this challenging condition.